This Article Full Text Full Text (PDF) Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Holmes, F. A. Articles by Liticker, J. D. Search for Related Content PubMed Articles by Holmes, F. A. Articles by Liticker, J. D. Social Bookmarking                            What's this?

Pharmacogenomics of Tamoxifen in a Nutshell—And Who Broke the Nutcracker?

Because this article has no abstract, we have provided an extract of the first 100 words of the full text.

Imagine biting into one of south Texas's most inviting sweets, a pecan pie, but with all the pecans still in their shells—not only insipid, but potentially dangerous. At the 2003 San Antonio Breast Cancer Symposium (San Antonio, TX, December 3-6, 2003), my heart sank when I learned that the activity of tamoxifen was almost completely inhibited when paroxetine was coadministered—a pairing I so frequently used for control of vasomotor symptoms. Subsequently, Stearns et al¹ published their evolved understanding of tamoxifen pharmacokinetics; it attracted the attention of the Cable News Network (CNN), and it was viewed widely by patients and their . . . [Click for More]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Castro Pharmacogenomics in the Clinic: New Questions About Tamoxifen J. Oncol. Pract, March 1, 2006; 2(2): 100 - 100. [Full Text] [PDF]